尼曼匹克病C型（NPC）治疗市场：依药物类型、适应症、通路及地区划分

预计到 2026 年，尼曼匹克病 C 型 (NPC) 治疗市场规模将达到 1.009 亿美元，到 2033 年将达到 4.06 亿美元。预计从 2026 年到 2033 年，该市场将以 22% 的复合年增长率成长。

尼曼-匹克病C型（NPC）是一种罕见的遗传性疾病。这种基因突变会导致胆固醇和其他脂质在肝臟、脾臟或肺部积聚，也会影响大脑。 NPC的症状出现时间随年龄而异，分为婴儿期（出生至6岁以下）、青少年期（6至15岁）及成年期（15岁以上）。在婴儿期，NPC可导致α1-抗胰蛋白酶缺乏症、酪胺酸血症、高雪氏症、特发性新生儿胆汁淤积症以及各种性行为感染等疾病。

市场动态

预计在预测期内，各国政府加大对罕见疾病的投入将推动全球尼曼-匹克病C型（NPC）治疗市场的成长。例如，2021年11月，义大利参议院一致通过了一项关于罕见疾病的统一法案。该法案旨在统一义大利全国的罕见疾病治疗标准，并加快相关研究的进展。此外，该法案还规定设立一个罕见疾病患者互助基金，初始累计为每年101万美元，自2022年起生效。

预计在预测期内，市场相关人员之间合作与协议的增加将推动全球尼曼-匹克病C型（NPC）治疗市场的成长。例如，2022年5月，专业製药公司Kempharm, Inc.宣布与全球生物製药公司ORPHAZYME A/S达成协议，收购arimochromol，这是一种口服的、First-in-Class的热休克蛋白（HSP）扩增剂，目前正在开发用于治疗尼曼-匹克病C型（NPC）。

预计市场参与企业研发活动的活性化将推动预测期内的市场成长。例如，2021年6月，临床阶段生物技术公司Cyclo Therapeutics, Inc.宣布启动一项III期主要临床试验（TransportNPC），以评估Trappsol Cyclo（一种专有的羟丙基β-环糊精製剂）治疗NPC1的疗效。 TransportNPC试验是一项随机、双盲、安慰剂对照、平行组、多中心研究，旨在评估静脉注射Trappsol Cyclo 2000 mg/kg联合标准治疗（SOC）与静脉注射NPC1患者的安全性、耐受性和有效性。

本次考试的主要特点。

• 本报告以 2021 年为基准年，对全球尼曼匹克病 C 型 (NPC) 治疗市场进行了详细分析，并预测了其在预测期 (2022-2030 年) 内的市场规模。
• 本报告指出了各个细分市场的潜在商机，并说明了该市场中具有吸引力的投资提案矩阵。
• 此外，本研究还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、区域前景以及主要企业采取的竞争策略的重要见解。
• 本报告根据以下参数对全球尼曼匹克病 C 型 (NPC) 治疗市场的主要企业进行了分析：公司概况、财务业绩、产品系列、地理分布、分销策略、关键发展和策略以及未来计划。
• 透过利用本报告中提出的见解，企业行销负责人和经营团队可以就未来的产品发布、技术升级、市场扩张和行销策略做出明智的决策。
• 本报告面向该行业的众多相关人员，包括投资者、供应商、製造商、经销商、新参与企业和金融分析师。
• 相关人员可以利用分析全球尼曼-匹克病 C 型 (NPC) 治疗市场中使用的各种策略矩阵来促进决策。

目录

第一章：研究目标与前提条件

• 研究目标
• 前提
• 简称

第二章 市场概览

• 报告摘要
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map（COM）

第三章：市场动态、监管与趋势分析

• 市场动态
  • 促进因素
  • 阻碍因素
  • 市场机会
• 影响分析
• 波特的分析
• 产业趋势
• 管道分析
• 主要亮点
• 流行病学
• 还款状态
• 监理情势
• 产品上市及核准
• 收购与合作趋势

第四章 全球尼曼-匹克症C型（NPC）治疗市场：依药物类型划分，2026-2033年

• 第三期研究药物
• 非处方药

第五章 全球尼曼匹克症C型（NPC）治疗市场：依适应症划分，2026-2033年

• NPC1
• NPC2

第六章 全球尼曼-匹克病C型（NPC）治疗市场：依通路划分，2026-2033年

• 医院药房
• 网路药房
• 零售药房

第七章 全球尼曼-匹克病C型（NPC）治疗市场：依地区划分，2026-2033年

• 北美洲
  • 我们
  • 加拿大
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 亚太其他地区
• 中东
  • GCC
  • 以色列
  • 其他中东国家
• 非洲
  • 南非
  • 中非
  • 北非

第八章 竞争情势

• 公司简介
  • Johnson &Johnson
  • Intrabio
  • Cyclo Therapeutics, Inc.
  • Kempharm, Inc
  • Azafaros BV
  • StrideBio
  • Sarepta Therapeutics, Inc.

第九章

• 调查方法
• 分析师意见
• 关于本公司
• 询问

Niemann-Pick Disease Drug Type C Treatment Market is estimated to be valued at USD 100.9 Mn in 2026 and is expected to reach USD 406.0 Mn by 2033, growing at a compound annual growth rate (CAGR) of 22% from 2026 to 2033.

Niemann-Pick Type C (NPC) is a rare inherited disease. This type of genetic mutation causes cholesterol and other fats to build up in the liver, spleen, or lungs. It has an impact on the brain as well. The onset of symptoms for NPC may begin at different ages. It has been grouped as: infantile (after birth to less than 6 years), juvenile (6 to 15 years), and adults (15 years to greater). In infants, NPC leads to disorders such as alpha-1-antitrypsin deficiency, tyrosinemia, Gaucher disease, idiopathic neonatal cholestasis, and various congenital infections.

Market Dynamics

Increasing government initiatives for rare diseases is expected to foster global niemann-pick disease type C treatment market growth over the forecast Period. For instance, in November 2021, the Italian senate unanimously approved the consolidated act on rare diseases. The aim of the act is to make the treatment of rare diseases uniform throughout the Italian territory and to promote progress in research. Moreover, the act also provides for the establishment of solidarity fund for people with rare diseases, with an initial budget of US$ 1.01 million per year starting from 2022.

Rising numbers of collaborations and agreements by market players are expected to drive growth of the global Niemann-pick disease drug type C treatment market over the forecast period. For instance, in May 2022, Kempharm, Inc., a specialty pharmaceutical company, announced an agreement with ORPHAZYME A/S, a global biopharmaceutical company, to acquire arimoclomol, an orally-delivered, first-in-class heat shock protein (HSP) amplifier being developed as a treatment for Niemann-Pick disease type C (NPC)

Increasing research and development activities by market players are expected to drive growth of market over the forecast period. For instance, in June 2021, Cyclo Therapeutics, Inc., a clinical-stage biotechnology company, announced the commencement of its pivotal Phase 3 study (TransportNPC) for the evaluation of Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin, delivered intravenously, for treating Niemann-Pick Disease Type C1 (NPC1). The TransportNPC study is a randomized, double-blind, placebo-controlled, parallel group, multicenter study designed to evaluate the safety, tolerability, and efficacy of 2,000 mg/kg of Trappsol Cyclo administered intravenously and standard of care (SOC) compared to placebo administered intravenously and SOC in patients with NPC1.

Key features of the study

• This report provides an in-depth analysis of the global Niemann-pick disease drug type C treatment market , market size (US$ Million), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in the global Niemann-pick disease drug type C treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
• Key companies covered as a part of this study include Livewise Johnson & Johnson, Intrabio, Cyclo Therapeutics, Inc., Kempharm, Inc., Azafaros B.V., StrideBio. Sarepta Therapeutics, Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make an informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The global Niemann-pick disease drug type C treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global Niemann-pick disease drug type C treatment market

Market Segmentation

• By Drug Type
  • Phase III Drug
  • Trappsol Cyclo
  • IB1001
  • Marketed Drug
  • Miglustat (Zavesca)
• By Indication
  • Niemann-Pick Disease Drug Type C1
  • Niemann-Pick Disease Drug Type C2
• By Distribution Channel
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
• By Region
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa
  • GCC Countries
  • Israel
  • Rest of Middle East & Africa
• Global Niemann-Pick Disease Drug Type C Treatment Market - Competitive Landscape
  • Johnson & Johnson
  • Intrabio
  • Cyclo Therapeutics, Inc.
  • Kempharm, Inc.
  • Azafaros B.V.
  • StrideBio
  • Sarepta Therapeutics, Inc.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Type
  • Market Snippet, By Indication
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Porter's Analysis
• Industry Trends
• Pipeline Analysis
• Key Highlights
• Epidemiology
• Reimbursement Scenario
• Regulatory Scenario
• Product Launch and Approvals
• Acquisition and Collaboration Scenario

4. Global Niemann-Pick Disease Drug Type C Treatment Market, By Drug Type, 2026-2033 (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Phase III Drug
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
    • Trappsol Cyclo
    • IB1001
• Marketed Drug
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
    • Miglustat (Zavesca)

5. Global Niemann-Pick Disease Drug Type C Treatment Market, By Indication, 2026-2033 (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Niemann-Pick Disease Drug Type C1
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Niemann-Pick Disease Drug Type C2
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

6. Global Niemann-Pick Disease Drug Type C Treatment Market, By Distribution Channel, 2026-2033 (US$ Million)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2026-2033
  • Segment Trends
• Hospitals Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2026-2033, (US$ Million)

7. Global Niemann-Pick Disease Drug Type C Treatment Market, By Region, 2026-2033 (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, For Regions, 2026-2033
  • Regional Trends
• North America
  • Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Distribution Channels, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
    • U.S.
    • Canada
• Latin America
  • Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Distribution Channels, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Distribution Channel, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Distribution Channels, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Country, 2026-2033 (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Market Size and Forecast, By Drug Type, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Indication, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Distribution Channels, 2026-2033 (US$ Mn)
  • Market Size and Forecast, By Country/Region, 2026-2033 (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

8. Competitive Landscape

• Company Profiles
  • Johnson & Johnson
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Intrabio
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Cyclo Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Kempharm, Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Azafaros B.V
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • StrideBio
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Sarepta Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies

9. Section

• Research Methodology
• Analyst Views
• About us
• Contact